CO2024010940A2 - Formulación líquida de toxina botulínica y uso de la misma - Google Patents
Formulación líquida de toxina botulínica y uso de la mismaInfo
- Publication number
- CO2024010940A2 CO2024010940A2 CONC2024/0010940A CO2024010940A CO2024010940A2 CO 2024010940 A2 CO2024010940 A2 CO 2024010940A2 CO 2024010940 A CO2024010940 A CO 2024010940A CO 2024010940 A2 CO2024010940 A2 CO 2024010940A2
- Authority
- CO
- Colombia
- Prior art keywords
- liquid formulation
- botulinum toxin
- present
- tryptophan
- mixture
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 5
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 2
- 229940053031 botulinum toxin Drugs 0.000 title abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 3
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002738 chelating agent Substances 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 abstract 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- -1 iron ions Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940116191 n-acetyltryptophan Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156843 | 2022-02-15 | ||
| EP22183172 | 2022-07-05 | ||
| PCT/EP2023/053647 WO2023156389A1 (en) | 2022-02-15 | 2023-02-14 | Liquid botulinum toxin formulation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024010940A2 true CO2024010940A2 (es) | 2024-09-19 |
Family
ID=85202119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0010940A CO2024010940A2 (es) | 2022-02-15 | 2024-08-12 | Formulación líquida de toxina botulínica y uso de la misma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250152682A1 (https=) |
| EP (1) | EP4479023A1 (https=) |
| JP (1) | JP2025504249A (https=) |
| KR (1) | KR20240141340A (https=) |
| CN (1) | CN119031902A (https=) |
| AR (1) | AR128514A1 (https=) |
| AU (1) | AU2023221507A1 (https=) |
| CA (1) | CA3243238A1 (https=) |
| CO (1) | CO2024010940A2 (https=) |
| IL (1) | IL315004A (https=) |
| MX (1) | MX2024009970A (https=) |
| TW (1) | TW202348248A (https=) |
| WO (1) | WO2023156389A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
| WO2026021713A1 (en) | 2024-07-23 | 2026-01-29 | Merz Therapeutics GmbH | Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| JP2006045173A (ja) * | 2004-08-09 | 2006-02-16 | Hidetoshi Tsuchida | 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液 |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| CA2766649C (en) * | 2009-06-24 | 2016-08-23 | Charles N.S. Soparkar | Zinc supplementation to increase responsiveness to metalloprotease therapy |
| ES2653249T3 (es) | 2011-09-29 | 2018-02-06 | Cellsnap, Llc | Composiciones y métodos para ensayos de toxigenicidad |
| AU2014301116B2 (en) | 2013-06-28 | 2019-11-14 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells |
| PL3463432T3 (pl) * | 2016-05-27 | 2021-04-19 | Ipsen Biopharm Limited | Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną |
-
2023
- 2023-02-14 IL IL315004A patent/IL315004A/en unknown
- 2023-02-14 US US18/838,555 patent/US20250152682A1/en active Pending
- 2023-02-14 WO PCT/EP2023/053647 patent/WO2023156389A1/en not_active Ceased
- 2023-02-14 JP JP2024547688A patent/JP2025504249A/ja active Pending
- 2023-02-14 CA CA3243238A patent/CA3243238A1/en active Pending
- 2023-02-14 KR KR1020247030641A patent/KR20240141340A/ko active Pending
- 2023-02-14 CN CN202380033828.4A patent/CN119031902A/zh active Pending
- 2023-02-14 AU AU2023221507A patent/AU2023221507A1/en active Pending
- 2023-02-14 AR ARP230100336A patent/AR128514A1/es unknown
- 2023-02-14 TW TW112105172A patent/TW202348248A/zh unknown
- 2023-02-14 EP EP23704176.9A patent/EP4479023A1/en active Pending
- 2023-02-14 MX MX2024009970A patent/MX2024009970A/es unknown
-
2024
- 2024-08-12 CO CONC2024/0010940A patent/CO2024010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009970A (es) | 2024-09-18 |
| US20250152682A1 (en) | 2025-05-15 |
| AR128514A1 (es) | 2024-05-15 |
| KR20240141340A (ko) | 2024-09-26 |
| TW202348248A (zh) | 2023-12-16 |
| CN119031902A (zh) | 2024-11-26 |
| JP2025504249A (ja) | 2025-02-06 |
| WO2023156389A1 (en) | 2023-08-24 |
| CA3243238A1 (en) | 2023-08-24 |
| EP4479023A1 (en) | 2024-12-25 |
| IL315004A (en) | 2024-10-01 |
| AU2023221507A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024010940A2 (es) | Formulación líquida de toxina botulínica y uso de la misma | |
| Muguerza et al. | Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats | |
| BR112021002069A2 (pt) | Composição para tratamento capilar, métodos e usos da mesma. | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| BRPI0509505A (pt) | método e kit útil para branqueamento de uma superfìcie dental | |
| El Ayadi et al. | Metal chelation attenuates oxidative stress, inflammation, and vertical burn progression in a porcine brass comb burn model | |
| DE602004019956D1 (de) | Zubereitungen für die topische anwendung und verfahren zur abgabe eines wirkstoffs an ein substrat | |
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| Tanaka et al. | Pyruvic acid prevents Cu2+/Zn2+-induced neurotoxicity by suppressing mitochondrial injury | |
| Fteita et al. | Does estradiol have an impact on the dipeptidyl peptidase IV enzyme activity of the Prevotella intermedia group bacteria? | |
| MX2021013142A (es) | Metodos para usar antioxidantes en composiciones para el tratamiento de telas para tratar telas que contienen elastano. | |
| ECSP23024034A (es) | Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped | |
| CO5570661A2 (es) | Combinaciones que comprenden inhibidores de cox-2 y aspirina | |
| Liu et al. | Oleic acid induces lipogenesis and NLRP3 inflammasome activation in organotypic mouse meibomian gland and human meibomian gland epithelial cells | |
| MX2024005052A (es) | Composicion farmaceutica y kit que comprende una sustancia inmunomoduladora para tratar enfermedades. | |
| FR3130140B1 (fr) | Agent de traitement capillaire avec effet de soin amélioré | |
| RU2004101940A (ru) | Средство для лечения воспалительных и дегенеративных заболеваний суставов, имплантант синовиальной жидкости, способ лечения воспалительных и дегенеративных заболеваний суставов (варианты) и устройство для доставки лекарственного средства к поражённому участку | |
| Abu-Dief et al. | Impact of omega-3 fatty acids on evolution of carbon tetrachloride-(CCl4) induced liver cirrhosis in mice: A histological and immunohistochemical study | |
| AR054435A1 (es) | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad | |
| DK0432638T3 (da) | Kombinationspræparater omfattende chloramphenicol, gentamycin og nystatin som virksomme stoffer til topisk behandling af inflammatoriske hudsygdomme | |
| Ma et al. | N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis | |
| TW201900150A (zh) | 一種具抗老化、美白、抗過敏及細胞修護之紅藜萃取物 | |
| TWI724210B (zh) | 一種具抗老化、美白、抗過敏及細胞修護之龍眼花萃取物 | |
| Requena et al. | Sclerosing panniculitis | |
| CO2026001534A2 (es) | Formulación líquida de toxina botulínica y su uso |